These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Long-term outcome of advanced hepatocellular carcinoma that received transarterial hepatic chemotherapy].
    Author: Masutani S, Shimizu J, Tatsuta M, Masuda F, Imamura H, Ishida H, Furukawa H, Tomotsu K, Yura M, Obana T, Kitamura S, Saeki N, Inoue Y, Takamura M, Ohnishi H.
    Journal: Gan To Kagaku Ryoho; 2003 Oct; 30(11):1579-82. PubMed ID: 14619468.
    Abstract:
    Nineteen patients with far advanced hepatocellular carcinoma received transarterial hepatic chemotherapy. Twelve patients were Child-Pugh A, 2 were B, and 2 were C. Seventeen patients had portal vein thrombus, and 2 patients had extra-hepatic metastasis. Among the 19 patients, 13 received low-dose CDDP and 5-FU, and 5-FU with interferon was performed in 2. Lipiodol chemotherapy with epirubicin and MMC was performed after first-line chemotherapy, following the evaluation of the progressive disease. The 1- and 3-year survival rates in all cases were 42.5% and 18.2%, respectively. Of the 18 patients evaluated for response, 1 showed complete response, 2 showed partial responses, 8 had stable disease, and 7 progressed. Median survival time of CR, PR and SD patients was 14.2 months. A multivariate analysis identified CLIP score and therapeutic effect as independent predictors for mortality. It is concluded that transarterial hepatic chemotherapy was very useful for far advanced hepatocellular carcinoma.
    [Abstract] [Full Text] [Related] [New Search]